0000000001228891
AUTHOR
Luigi Di Lauro
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience
We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreat…
Thymosin α1 and α-Inteferon with Cisplatin and Etoposide in Advanced Non-Small-Cell Lung Cancer: A Phase II Study
In recent years, biological response modifiers (BRMs) have emerged as an important new class of agents for treating cancer. Agents such as interferon (IFN) and interleukin 2 (IL-2) have been reported to induce significant tumor regression in various types of cancer usually resistant to chemotherapy (1,12), but their use in non-small-cell lung cancer (NSCLC) has received little attention.